On February 19, Tom Lee of Fundstrat and BitMine joined ‘Closing Bell’ on CNBC to talk about the state of the markets. Lee described the current market environment as a slow turnaround following a series of hits, including a significant downturn in the software sector and a rotation away from the MAG7. Lee noted that investors have shifted focus toward the bullet makers of AI, while a general risk-off sentiment has been magnified by a surge in gold prices. Despite this, he remains optimistic because corporate earnings have been delivered solidly and economic reports remain strong.
Lee emphasized that the current earnings season has been strong, with a large percentage of companies reporting significant beats. However, he argued that stock prices have not yet fully reflected this fundamental strength because market multiples have been pressured by external factors, including a new Fed Chair, AI-related uncertainty, and the potential for war. Lee pointed out three key traits that he is watching for a market recovery: a rotation back into the MAG7, a bottoming out of the software sector, and a bottoming out of the crypto market.
That being said, we’re here with a list of the 10 best NASDAQ growth stocks to buy for the next 2 years.
Our Methodology
We used screeners to identify stocks that have a track record of delivering earnings growth as well as positive growth expectations. We looked for companies listed on the NASDAQ that have grown their EPS by at least 20% over the trailing twelve months and are expected to grow their EPS by at least 20% over the next year. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on February 19.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10 Best NASDAQ Growth Stocks to Buy for the Next 2 Years
10. Ascendis Pharma (NASDAQ:ASND)
Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 11, Ascendis Pharma reported that it nearly doubled its total revenue for 2025 to €720 million, fueled by the rapid global adoption of its core endocrinology products. Q4 was particularly significant, as the company achieved an operating profit of €10 million and generated €73 million in operating cash flow. This was largely driven by YORVIPATH, which brought in €477 million for the full year, and the steady performance of SKYTROFA, which contributed €206 million.
Despite a full-year net loss of €228 million due to commercial investments, the company ended the year with a solid cash position of €616 million, supported by a $100 million partnership payment from Novo Nordisk. The company’s success is rooted in its proprietary TransCon tech platform, which transforms established drugs into long-acting, once-weekly prodrugs. By linking parent drugs to an inert carrier via a temporary linker, TransCon ensures a predictable and sustained release of the active medication.
This has allowed Ascendis Pharma (NASDAQ:ASND) to secure a dominant 45% share of the US long-acting growth hormone market for SKYTROFA. Management is now preparing for the next major growth phase with the anticipated FDA approval of TransCon CNP for pediatric achondroplasia, which has a PDUFA action date of February 28, 2026, and is expected to provide a new therapeutic option beyond simple linear growth.
Ascendis Pharma (NASDAQ:ASND) is a biopharmaceutical company that develops TransCon-based (Transient Conjugation) therapies for unmet medical needs in Europe, the US, and internationally.
9. MKS Inc. (NASDAQ:MKS)
MKS Inc. (NASDAQ:MKS) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 17, MKS Inc. reported revenue of $1.03 billion for Q4 2025, which is a 10% increase year-over-year. This growth was driven by the Electronics & Packaging segment, which surged 19% compared to the prior year, due to capacity expansions in chemistry and flex drilling equipment. The company concluded the full year with $3.9 billion in total revenue.
A primary driver for the company’s current success is the rapid adoption of AI technology, which is reshaping its revenue mix. AI-related boards require significantly more layers than standard smartphone components, doubling AI chemistry revenue from 5% to 10% of total chemistry sales in 2025. Additionally, the company is benefiting from a memory crunch in the semiconductor industry. As fabs expand to meet DRAM and NAND demand for AI, MKS is seeing increased orders for its RF power solutions used in high-intensity vertical channel etching.
For 2026, MKS Inc. (NASDAQ:MKS) issued Q1 revenue guidance of $1.04 billion. While the company expects a seasonal dip in specialty industrial sales due to the Lunar New Year, it is preparing for a mid-year capacity boost with the opening of a new supercenter factory in Malaysia.
MKS Inc. (NASDAQ:MKS) provides foundational technology solutions to semiconductor manufacturing, electronics & packaging, and specialty industrial applications internationally. It operates through the Vacuum, Photonics, and Material Solutions Division segments.
8. Genmab (NASDAQ:GMAB)
Genmab (NASDAQ:GMAB) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 17, Genmab reported that its total revenue grew by 19% in 2025 to a total $3.7 billion. This growth was fueled by a 54% surge in sales of its proprietary medicines, most notably Abkinley, which generated $468 million, which was a 67% year-over-year increase. The company also benefited from the continued success of its royalty portfolio, particularly Darzalex, which is projected to reach net sales of up to $16.4 billion in 2026.
The company strategically expanded throughout the year, highlighted by the acquisition of ProfoundBio and its promising late-stage asset, Rina-S. Genmab particularly expanded its clinical pipeline with three new Phase 3 trials and secured FDA approval for Abkinley in second-line follicular lymphoma.
However, the company faced a hurdle with the Phase 3 EPCOR DLBCL-1 trial: while Genmab (NASDAQ:GMAB) met its progression-free survival goals, it missed statistical significance for overall survival, leading to ongoing discussions with regulatory authorities to address trial biases like COVID-19 and the impact of subsequent therapies.
Genmab (NASDAQ:GMAB) is a biotechnology company that develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
7. Grab Holdings Limited (NASDAQ:GRAB)
Grab Holdings Limited (NASDAQ:GRAB) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 11, Grab Holdings reported its first full year of net profitability with a net profit of $200 million in 2025. Group revenue rose 19% to $906 million for Q4, which was driven by a 21% surge in On-Demand GMV across its mobility and delivery sectors. The company’s focus on a product-led affordability strategy successfully expanded its user base to over 129 million annual transacting users.
A major highlight of the quarter was Grab’s move into international wealth management through the $425 million acquisition of Stash Financial, which is a US-based digital investing platform. This acquisition is expected to support Grab’s financial services roadmap by integrating Stash’s AI-powered investing tools into the Southeast Asian ecosystem.
Looking toward 2026, Grab Holdings Limited (NASDAQ:GRAB) issued upbeat guidance with revenue expected to reach between $4.04 billion and $4.10 billion, representing a 20% to 22% year-over-year increase. The company is doubling down on technological innovation, with over 90% of mobility rides now dispatched via AI and a growing fleet of 20,000 electric vehicles being deployed through a new partnership with GAC.
Grab Holdings Limited (NASDAQ:GRAB) offers the Grab ecosystem, which is a single platform with superapps for driver and merchant-partners and consumers for mobility, delivery, and digital financial services. It has four segments: Deliveries, Mobility, Financial Services, and Others. The company
6. MACOM Technology Solutions Holdings Inc. (NASDAQ:MTSI)
MACOM Technology Solutions Holdings Inc. (NASDAQ:MTSI) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 5, MACOM Technology Solutions delivered revenue of $271.6 million for FQ1 2026, which was a 24.5% year-over-year increase, while adjusted EPS totaled $1.02. Industrial & Defense and Data Center markets are reaching all-time high revenue levels of $117.7 million and $85.8 million, respectively.
The Data Center segment prompted management to raise its full-year growth outlook from 20% to a range of 35% to 40%. This is attributed to the rapid transition toward 1.6T optical products and sustained demand for 800G analog solutions among hyperscalers. To support this momentum, MACOM is expanding its photonics portfolio and manufacturing capacity, particularly for 200G-per-lane photodetectors and new CW lasers, while continuing to integrate its RTP fab to improve cycle times and long-term gross margins.
However, the company faces some headwinds, including a flat outlook for the broader telecom market and production delays on a $55 million satellite contract due to customer-driven system changes. For FQ2, the company has guided for continued growth with revenues between $281 million and $289 million.
MACOM Technology Solutions Holdings Inc. (NASDAQ:MTSI), together with its subsidiaries, provides analog semiconductor solutions for use in wireless and wireline applications across the radio frequency, microwave, millimeter wave, and lightwave spectrum.
5. Rivian Automotive Inc. (NASDAQ:RIVN)
Rivian Automotive Inc. (NASDAQ:RIVN) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 12, Rivian Automotive reported total revenue of $1.3 billion for Q4 2025. While the automotive segment faced a gross loss of $59 million during the quarter, the company’s software and services division proved highly profitable, generating $179 million in gross profit with margins in the mid-30% range.
Rivian ended the year with $6.1 billion in liquidity, which was supported by the progress of its joint venture with Volkswagen Group, which contributed significantly to the company’s software revenue growth. The company is now pivoting toward the mass market with the highly anticipated launch of the R2 vehicle, expected to begin deliveries in Q2 2026. This new model aims to fill a market gap for premium electric vehicles priced near $50,000 and has already generated a strong demand backlog.
However, management cautioned that the complexity of the R2 production ramp-up, combined with capital expenditures for tooling and construction, will likely lead to an adjusted EBITDA loss between $1.8 billion and $2.1 billion for 2026. Despite potential production bottlenecks and a predicted dip in automotive margins during mid-2026, Rivian Automotive Inc. (NASDAQ:RIVN) remains focused on a full-year delivery target of 62,000 to 67,000 vehicles.
Rivian Automotive Inc. (NASDAQ:RIVN), together with its subsidiaries, develops, manufactures, and sells category-defining electric vehicles. It has two segments: Automotive and Software & Services.
4. Incyte Corporation (NASDAQ:INCY)
Incyte Corporation (NASDAQ:INCY) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 10, Incyte Corporation reported that the company’s Q4 2025 revenue climbed 28% to $1.51 billion, while full-year sales reached $5.14 billion. The company’s growth was largely propelled by its flagship product, Jakafi, which achieved annual sales of $3.093 billion, and the rapid expansion of Opzelura in the atopic dermatitis and vitiligo markets.
The company’s core business, excluding Jakafi, grew by 53% year-over-year in the final quarter. Key contributors included the hematology and oncology franchise, featuring Niktimvo and Monjuvi, which saw a 121% quarterly revenue surge. Incyte’s R&D efforts also reached a new level of maturity in 2025, with timely regulatory submissions for Jakafi XR and povercinib. Management expects this momentum to continue into 2026, forecasting core business growth of over 30% as the company moves towards a goal of 14 pivotal clinical trials by year-end.
Incyte Corporation (NASDAQ:INCY) now aims to nearly double its business size through a combination of internal innovation and strategic business development. While the company anticipates a mid-single-digit sales increase for Jakafi in 2026, it is heavily investing in next-gen treatments, such as its KRAS program and frontline DLBCL therapies.
Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in the US, Europe, Canada, and Japan. The company has collaboration and license agreements with Novartis, Lilly, and Syndax.
3. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 12, Alnylam Pharmaceuticals reported its earnings for 2025, with nearly $3 billion in total revenue, which was an 81% increase year-over-year. Q4 was particularly strong, with net product revenue reaching $995 million, fueled by a 151% year-over-year surge in the TTR franchise following the successful launch of Amphotra for ATTR cardiomyopathy.
In this quarter, Alnylam also launched Cyreli, which is a new RNAi manufacturing platform designed to expand capacity and reduce long-term costs. Looking ahead to 2026, the company issued optimistic guidance, forecasting combined net product sales between $4.9 billion and $5.3 billion, despite anticipating a modest mid-single-digit decrease in net pricing for its core products.
Leadership emphasized the strength of Alnylam Pharmaceuticals Inc.’s (NASDAQ:ALNY) internal pipeline, which includes over 25 active clinical programs. Executives also highlighted the potency of the company’s ACVR1C asset in the obesity space and the long-term potential for products like Nrierran to drive operating margins into the mid-40s by 2030.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the US, Europe, and internationally.
2. GlobalFoundries Inc. (NASDAQ:GFS)
GlobalFoundries Inc. (NASDAQ:GFS) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 16, GlobalFoundries and Renesas Electronics Corporation announced a multi-billion-dollar partnership to strengthen semiconductor supply chain resiliency. This collaboration expands Renesas’ access to GlobalFoundries’ specialized technology platforms, including FDX, BCD, and feature-rich CMOS technologies.
The agreement aligns with US priorities to support domestic chip production while supporting the increasing demand for semiconductors in smart vehicles, industrial IoT, and next-gen automated systems. The partnership uses GlobalFoundries’ global manufacturing footprint, with initial production focused in the US before extending to facilities in Germany, Singapore, and China. Furthermore, the companies are exploring the option of porting specific GlobalFoundries Inc. (NASDAQ:GFS) process technologies into Renesas’ internal fabrication plants in Japan to enhance manufacturing flexibility.
Tape-outs for these advanced SoCs, power devices, and microcontrollers are scheduled to begin in mid-2026 to address global requirements for electrification and AI-driven applications. Leaders from both organizations emphasized that this deal secures a stable, long-term supply of essential components for the automotive and industrial sectors.
GlobalFoundries Inc. (NASDAQ:GFS) is a semiconductor foundry that provides a range of mainstream wafer fabrication services and technologies worldwide.
1. Nvidia Corporation (NASDAQ:NVDA)
Nvidia Corporation (NASDAQ:NVDA) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 18, Nvidia announced a multiyear agreement to supply Meta Platforms with millions of artificial intelligence chips and central processing units. This deal includes the current Blackwell architecture alongside the forthcoming Rubin AI chips. Notably, the partnership also incorporates standalone installations of Nvidia’s Grace and Vera CPUs, which use Arm Holdings technology to compete directly against established processors from Intel and AMD.
The inclusion of these central processors signals Nvidia’s expansion into markets beyond AI acceleration, specifically targeting high-intensity data processing and database management. The Grace CPUs have demonstrated the ability to perform common tasks using half the power of traditional hardware. Meta has already begun testing the next-gen Vera chips, with early results showing promise for backend data center operations.
This announcement comes as Meta continues to develop its own proprietary AI silicon and explores the use of Google’s TPUs. While the specific financial value of the deal was not disclosed, analysts suggest the move highlights Nvidia Corporation’s (NASDAQ:NVDA) ability to retain Meta as a major customer while gaining traction for its CPU lineup.
Nvidia Corporation (NASDAQ:NVDA) is a computing infrastructure company that provides graphics compute & networking solutions in the US, Singapore, Taiwan, China, Hong Kong, and internationally.
While we acknowledge the potential of NVDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVDA and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
